drugset / Trial / NCT05085548
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is a first-in-human, Phase I study to assess the safety of ProAgio in participants with advanced solid tumor malignancies including pancreatic cancer.
Timeline
- Start
- 2021-10-29
- Primary completion
- 2025-04-24
- Completion
- 2026-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ProAgio | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | — |